275 S Bryn Mawr Ave, F18,
182 articles about Bristol-Myers Squibb
X-Chem Enters Strategic Collaboration with Bristol-Myers Squibb
X-Chem, Inc., a privately held biotechnology company focused on applying its industry-leading DNA-encoded (DEX™) library drug discovery engine to the generation of novel small molecule therapeutics, today announced the signing of a broad strategic drug discovery collaboration with Bristol-Myers Squibb. T
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
Bristol-Myers Squibb Provides Update on the Ongoing Regulatory Review of Opdivo Plus Low-Dose Yervoy in First-Line Lung Cancer Patients with Tumor Mutational Burden ≥10 mut/Mb
Bristol-Myers Squibb Company (NYSE:BMY) announced updates regarding regulatory actions by health authorities in the United States (U.S.) and European Union (EU) for the ongoing review of its applications for an indication in metastatic first-line non-small cell lung cancer with Opdivo (nivolumab) plus low-dose Yervoy
Dallas Cowboys Quarterback Dak Prescott, Modern Family Star Eric Stonestreet and Actress Tia Mowry Call on Americans to Rise Up Against Cancer Through Ready. Raise. Rise.
Trio Joins Bristol-Myers Squibb to Inspire People to Show How They Harness Their Unique Inner Power in the Fight Against Cancer
Preliminary Data for NKTR-214 in Combination with Opdivo (nivolumab) for Patients with Stage IV Metastatic Melanoma, Renal Cell Carcinoma, and Urothelial Cancers Presented at ASCO 2018
Nektar Therapeutics and Bristol-Myers Squibb announced presentation of preliminary data from the ongoing PIVOT Phase 1/2 Study.
Bristol-Myers Squibb and Biogen Are the Pharmas Most Trusted by Doctors, Study Finds
Doctors surveyed for Taking the Pulse® U.S., the longest-running U.S. study of online physician attitudes and multichannel behaviors, rated Bristol-Myers Squibb and Biogen as the most "trusted partners" based on recent digital interactions.
Bristol-Myers Squibb and Flatiron Health Expand Collaboration with a Three-Year Agreement
Strengthens Real-World Data Capabilities in Oncology Research at BMS
Lupus Research Alliance and Lupus Therapeutics Collaborate with Bristol-Myers Squibb on a New Lupus Trial
The Lupus Research Alliance today announced a collaboration between its newly formed affiliate, Lupus Therapeutics, and the pharmaceutical company, Bristol-Myers Squibb (BMS), to test a novel investigational drug, BMS-986165, as a potential new therapy for lupus.
Immuno-Oncology Sector Deals Dominate 2017 Life Sciences Deal of the Year Awards
Bristol-Myers Squibb acquisition of IFM Therapeutics, and Amgen-CytomX licensing deal recognized among more than 4,000 transactions in annual Cortellis Deal of the Year Awards from Clarivate Analytics
IFM Therapeutics and Bristol-Myers Squibb Awarded 2017 Deal of the Year by Clarivate Analytics
Deal of the Year Highlights Bristol-Myers Squibb's Acquisition of IFM's Preclinical STING and NLRP3 Agonist Programs
The possibility of a tax bill being passed has many investors and analysts forecasting 2018 to be a big year for mergers and acquisitions.
Seattle Genetics and Bristol-Myers Squibb Highlight Interim Results From Phase 1/2 Study Evaluating the Combination of ADCETRIS (Brentuximab Vedotin) and Opdivo (Nivolumab) in Relapsed or Refractory Hodgkin Lymphoma
The data were also simultaneously published online in the journal Blood.
Week in Review: China Life Science Deals Total $550M
Pfizer acquired China/Asia rights for Cresemba, an antifungal drug developed by Swiss pharma Basilea, in a $226M deal.
Ayala Pharmaceuticals, Founded by Israel Biotech Fund, aMoon and Harel Insurance, Enters Exclusive Worldwide License Agreement with Bristol-Myers Squibb (BMS) to Develop Cancer Treatments
Under the terms of the license agreement, Ayala will have exclusive worldwide development and commercialization rights for BMS-906024 and BMS-986115, two gamma secretase inhibitors previously developed by BMS as a Notch inhibitor for oncology indications.
Bristol-Myers Squibb and Pfizer Alliance Urge People to ‘Tune in to AFib, Take Note of Stroke Risk’
The Bristol-Myers Squibb and Pfizer Alliance, the National Stroke Association and iHeartMedia today launched ‘Tune in to AFib, Take Note of Stroke Risk’ to educate the estimated nearly seven million Americans in 2017 living with atrial fibrillation (AFib) not caused by a heart valve problem about their increased risk of stroke.
Bristol-Myers' Opdivo Demonstrates Superior Three-Year Survival Benefit for Patients With Previou...
11/6/2017No new safety signals were identified and the data showed a safety profile consistent with two-year results.
Bristol-Myers Squibb Presents Researching Personalized Medicine for the Potential Treatment of Autoimmune Diseases at 2017 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting
Bristol-Myers Squibb today confirmed that 34 abstracts related to ORENCIA (abatacept) and the Company’s immunoscience pipeline
Bristol-Myers Squibb recognizes JLL for Service Delivery Excellence
JLL has been recognized by global biopharmaceutical company Bristol-Myers Squibb with a Service Delivery Excellence Award announced at the company’s annual Global Suppliers Conference.
BioGeneration Ventures Fund III Reaches EUR 82 Million in Final Close
Due to strong market interest, the fund has exceeded its original target of EUR 50 million.
Bristol-Myers Squibb to Present New Data Advancing Research Across Serious Liver Diseases At The Liver Meeting 2017
Bristol-Myers Squibb Company today announced that new data across serious liver diseases, including nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC), will be presented at The Liver Meeting 2017 in Washington, DC, October 20 - 24, 2017.